查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1487659

外用抗生素市场 - 按药物类别、剂型、产品类型、药物类型、应用、配销通路、全球预测 2024 - 2032 年

Topical Antibiotics Market - By Drug Class, Dosage Form, Product Type, Medication Type, Application, Distribution Channel, Global Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于细菌和真菌感染等皮肤感染盛行率不断上升，预计 2024 年至 2032 年外用抗生素市场规模的复合年增长率将达到 5.4%。糖尿病足溃疡和压疮等慢性伤口的发生率不断上升，促使人们采用外用抗生素来治疗伤口和预防感染。根据着名医学杂誌《JAMA》报道，每年，糖尿病足溃疡影响全球约1860 万人，其中约160 万例发生在美国。将刺激人们对感染控制措施的重视。

製造商正在进一步开发创新配方，例如霜剂、软膏、凝胶和喷雾剂，以提高渗透性和持续释放特性，以优化药物传输并提高患者依从性。美容皮肤科越来越多地采用外用抗生素来治疗痤疮和其他皮肤病，加上消费者对非处方外用抗生素产品的需求不断增长，将有助于市场的扩张。

外用抗生素产业分为药品类别、剂型、产品类型、用药类型、应用、配销通路和地区。

到 2032 年，仿製药产品类型细分市场的市场规模预计将实现 5.9% 的复合年增长率。通用外用抗生素的可近性和可负担性使其对医疗保健提供者和患者更具吸引力。仿製药製造商也投资研发活动，以创造生物等效製剂，以确保与品牌製剂具有可比性的功效和安全性。

眼部感染应用领域的局部抗生素市占率预计在 2024 年至 2032 年期间将成长 5.5%。眼部感染，例如结膜炎和角膜炎，是由细菌或真菌病原体引起的常见眼部疾病，需要及时有效地使用局部抗生素进行治疗。与不良卫生习惯、隐形眼镜使用和环境因素相关的眼部感染盛行率不断上升，将增加对局部抗生素作为主要治疗介入的需求。

由于人口密度高和热带气候为细菌和真菌感染的传播创造了有利的环境，预计到 2032 年，亚太地区外用抗生素产业将获得动力并以 5.8% 的复合年增长率增长。在亚太地区人口稠密的城市地区和农村社区，结膜炎、脓疱病和皮肤真菌感染等传染病的发生率正在增加。中国、印度和东南亚国家等国家不断扩大的医疗基础设施和不断增长的可支配收入将推动外用抗生素的可及性，进一步推动区域市场的扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 皮肤感染的发生率增加
      • 抗生素抗药性上升
      • 扩大配方的进步
      • 不断增加的监管支持
    • 产业陷阱与挑战
      • 不良反应和安全问题
      • 偏好全身抗生素
  • 成长潜力分析
  • 管道分析
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按药物类别，2018 - 2032 年

  • 主要趋势
  • 四环素
  • 氨基糖苷类
  • 红霉素
  • 克林霉素
  • 其他药物类别

第 6 章：市场估计与预测：按剂型，2018 - 2032 年

  • 主要趋势
  • 药膏
  • 乳霜
  • 解决方案
  • 粉末
  • 其他剂型

第 7 章：市场估计与预测：按产品类型，2018 年 - 2032 年

  • 主要趋势
  • 品牌化
  • 泛型

第 8 章：市场估计与预测：按药物类型，2018 - 2032 年

  • 主要趋势
  • 场外交易 (OTC)
  • 处方

第 9 章：市场估计与预测：按应用划分，2018 年 - 2032 年

  • 主要趋势
  • 皮肤感染
  • 眼部感染
  • 耳部感染
  • 鼻腔感染
  • 其他应用

第 10 章：市场估计与预测：按配销通路划分，2018 年 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药局和药局
  • 网路药局

第 11 章：市场估计与预测：按地区划分，2018 年 - 2032 年

  • 主要动向：按地区
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 中东和非洲其他地区

第 12 章：公司简介

  • Almirall S.A.
  • Bausch Health Companies Inc.
  • Bayer AG
  • GlaxoSmithKline plc
  • Johnson & Johnson Consumer Inc.
  • Lupin
  • Medimetriks Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Mayne Pharma Group Limited.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
简介目录
Product Code: 8570

Topical antibiotics market size is predicted to witness 5.4% CAGR from 2024 to 2032, driven by the increasing prevalence of skin infections, including bacterial and fungal infections. The rising incidence of chronic wounds, such as diabetic foot ulcers and pressure ulcers is driving the adoption of topical antibiotics for wound management and infection prevention. As per well-known medical journal JAMA, every year, diabetic foot ulcers impact roughly 18.6 million individuals globally, with approximately 1.6 million cases occurring in the U.S. The growing awareness about the importance of infection control measures, particularly in healthcare settings, will stimulate the demand for topical antibiotics for the treatment and prevention of healthcare-associated infections.

Manufacturers are further developing innovative formulations, such as creams, ointments, gels, and sprays, with improved penetration and sustained release properties for optimizing drug delivery and enhancing patient compliance. The increasing adoption of topical antibiotics in cosmetic dermatology for the treatment of acne and other skin conditions, coupled with the rising consumer demand for OTC topical antibiotic products will contribute to the market expansion.

The topical antibiotics industry is divided into drug class, dosage form, product type, medication type, application, distribution channel, and region.

The market size from the generics product type segment is set to witness 5.9% CAGR up to 2032. As patents for branded topical antibiotics expire, generic versions have become available, leading to increased competition and lower prices. This accessibility and affordability of generic topical antibiotics makes them more attractive to healthcare providers and patients. Generic manufacturers are also investing in R&D activities to create bioequivalent formulations for ensuring comparable efficacy and safety to their branded counterparts.

Topical antibiotics market share from the eye infection application segment is anticipated to observe 5.5% growth rate during 2024-2032. Eye infections, such as conjunctivitis and keratitis, are common ocular conditions caused by bacterial or fungal pathogens, necessitating prompt and effective treatment with topical antibiotics. The increasing prevalence of eye infections, associated to poor hygiene practices, contact lens use, and environmental factors will contribute to the demand for topical antibiotics as the primary therapeutic intervention.

Asia Pacific topical antibiotics industry is anticipated to gain momentum and grow at a 5.8% CAGR through 2032, attributed to the high population density and tropical climate that creates conducive environments for the spread of bacterial and fungal infections. The incidence of infectious diseases, such as conjunctivitis, impetigo, and fungal skin infections, in densely populated urban areas and rural communities across APAC is increasing. The expanding healthcare infrastructure and the rising disposable incomes in countries like China, India, and Southeast Asian nations will fuel the accessibility of topical antibiotics, further driving the regional market expansion.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing incidence of skin infections
      • 3.2.1.2 Rising antibiotic resistance
      • 3.2.1.3 Expanding advancements in formulations
      • 3.2.1.4 Growing regulatory support
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Adverse effects and safety concerns
      • 3.2.2.2 Preference for systemic antibiotics
  • 3.3 Growth potential analysis
  • 3.4 Pipeline analysis
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Tetracycline
  • 5.3 Aminoglycoside
  • 5.4 Erythromycin
  • 5.5 Clindamycin
  • 5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Dosage Form, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Ointments
  • 6.3 Creams
  • 6.4 Solutions
  • 6.5 Powders
  • 6.6 Other dosage forms

Chapter 7 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Branded
  • 7.3 Generics

Chapter 8 Market Estimates and Forecast, By Medication Type, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Over-the-counter (OTC)
  • 8.3 Prescription

Chapter 9 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Skin infection
  • 9.3 Eye infection
  • 9.4 Ear infection
  • 9.5 Nasal infections
  • 9.6 Other applications

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 Hospital pharmacies
  • 10.3 Retail pharmacies & drug stores
  • 10.4 Online pharmacies

Chapter 11 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 11.1 Key trends, by region
  • 11.2 North America
    • 11.2.1 U.S.
    • 11.2.2 Canada
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 France
    • 11.3.4 Spain
    • 11.3.5 Italy
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 Rest of Asia Pacific
  • 11.5 Latin America
    • 11.5.1 Brazil
    • 11.5.2 Mexico
    • 11.5.3 Rest of Latin America
  • 11.6 Middle East and Africa
    • 11.6.1 South Africa
    • 11.6.2 Saudi Arabia
    • 11.6.3 Rest of Middle East and Africa

Chapter 12 Company Profiles

  • 12.1 Almirall S.A.
  • 12.2 Bausch Health Companies Inc.
  • 12.3 Bayer AG
  • 12.4 GlaxoSmithKline plc
  • 12.5 Johnson & Johnson Consumer Inc.
  • 12.6 Lupin
  • 12.7 Medimetriks Pharmaceuticals Inc.
  • 12.8 Merck & Co., Inc.
  • 12.9 Mayne Pharma Group Limited.
  • 12.10 Novartis AG
  • 12.11 Pfizer Inc.
  • 12.12 Sanofi
  • 12.13 Sun Pharmaceutical Industries Ltd.
  • 12.14 Teva Pharmaceutical Industries Ltd.
  • 12.15 Viatris Inc.